-transparent.png){kind=logo}
Relative dose ratios of the mineralocorticoid antagonists spironolactone (100 mg and 200 mg daily) and canrenoate-K (200 mg daily) at steady state were defined in six healthy subjects with fludrecortisone as the mineralocorticoid agonist. The urine log 10 Na/K responses during spironolactone treatments were consistent with the law of mass action. The potency of canrenoate-K was 0.68 (95% C.L. 0.53 to 0.89) that of spironolactone on a weight basis. Approximately 72% of the renal antimineralocorticoid activity of spironolactone could attributed to the metabolite canrenone. The results at steady state are contrasted with those of a previously study comparing single doses of spironolactone and canrenoate-K.
L Ramsay, and
M Asbury, and
J Shelton, and
I Harrison
May 1981,
Clinical pharmacology and therapeutics,
L Ramsay, and
M Asbury, and
J Shelton, and
I Harrison
June 1973,
The Journal of pharmacology and experimental therapeutics,
L Ramsay, and
M Asbury, and
J Shelton, and
I Harrison
March 1982,
Clinical pharmacology and therapeutics,
L Ramsay, and
M Asbury, and
J Shelton, and
I Harrison
October 1972,
Deutsche medizinische Wochenschrift (1946),
L Ramsay, and
M Asbury, and
J Shelton, and
I Harrison
January 1985,
Lancet (London, England),
L Ramsay, and
M Asbury, and
J Shelton, and
I Harrison
October 1972,
Deutsche medizinische Wochenschrift (1946),
L Ramsay, and
M Asbury, and
J Shelton, and
I Harrison
January 1984,
Minerva dietologica e gastroenterologica,
L Ramsay, and
M Asbury, and
J Shelton, and
I Harrison
December 1990,
Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete,
L Ramsay, and
M Asbury, and
J Shelton, and
I Harrison
March 1986,
Lancet (London, England),
L Ramsay, and
M Asbury, and
J Shelton, and
I Harrison
December 1977,
International journal of clinical pharmacology and biopharmacy,
